808 Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial of Mesalamine for the Prevention of Recurrence of Diverticulitis

Kruis, Wolfgang; Eisenbach, Thomas; Löhr, Hanns; Müser, Moritz; Tan, Gie; Lukáš, Milan; Vich, Tomás; Bunganič, Ivan; Pokrotnieks, Juris; Derova, Jelena; Kondrackienė, Jūratė; Safadi, Rifaat; Tuculanu, Daniel; Tulassay, Zsolt; Banai, János; Dilger, Karin; Greinwald, Roland; Mohrbacher, Ralf; Spiller, Robin

doi:10.1016/s0016-5085(13)60503-x

Cited by 12 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23,24 The predictive role of DICA may also explain why the majority of studies found mesalazine ineffective in preventing recurrence of AD. [25][26][27][28][29][30] We know that mesalazine seems to be effective at least in controlling symptoms following AD, but only in patients at the first attack of acute uncomplicated diverticulitis. 25,26 It is hypothesised that those patients have DICA 2 scores.…”

Section: Discussionmentioning

confidence: 99%

Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study

Tursi

Brandimarte

Mario

et al. 2016

United European Gastroenterology Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study

Tursi

Brandimarte

Mario

et al. 2016

United European Gastroenterology Journal

View full text Add to dashboard Cite

show abstract

“…105 Based on the efficiency in ulcerative colitis, six placebo-controlled trials have assessed whether mesalamine would reduce the risk of recurrent acute diverticulitis. [99][100][101][102][103] None of the 6 available trials showed a statistically significant benefit of mesalamine versus placebo in the prevention of recurrence. One study showed a potential trend towards reducing the risk of recurrence at 24 months, 101 and a post hoc analysis of another trial found a reduction in rectosigmoid symptoms.…”

Section: Discussionmentioning

confidence: 99%

American Gastroenterological Association Institute Technical Review on the Management of Acute Diverticulitis

2015

View full text Add to dashboard Cite

“…Seven double‐blind placebo‐controlled trials (four published, three unpublished) evaluating the use of mesalazine vs. placebo in preventing acute diverticulitis recurrence were identified . Mesalazine was used in doses ranging from 0.8 g for 10 days every month to 4.8 g daily.…”

Section: Medical Treatment Of Diverticulosis and Ddmentioning

confidence: 99%

“…Seven double-blind placebo-controlled trials (four published, three unpublished) evaluating the use of mesalazine vs. placebo in preventing acute diverticulitis recurrence were identified. [113][114][115][116][117] Mesalazine was used in doses ranging from 0.8 g for 10 days every month to 4.8 g daily. Most failed to find mesalazine significantly superior to placebo in preventing diverticulitis recurrence.…”

Section: Secondary Prevention Of Acute Diverticulitismentioning

confidence: 99%

Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon

Tursi

Papa²,

Danese

2015

Aliment Pharmacol Ther

120

View full text Add to dashboard Cite

Summary Background The incidence of diverticulosis and diverticular disease of the colon, including diverticulitis, is increasing worldwide, and becoming a significant burden on national health systems. Treatment of patients with diverticulosis and DD is generally based on high‐fibre diet and antibiotics, respectively. However, new pathophysiological knowledge suggests that further treatment may be useful. Aim To review the current treatment of diverticulosis and diverticular disease. Methods A search of PubMed and Medline databases was performed to identify articles relevant to the management of diverticulosis and diverticular disease. Major international conferences were also reviewed. Results Two randomised controlled trials (RCT) found the role of antibiotics in managing acute diverticulitis to be questionable, particularly in patients with no complicating comorbidities. One RCT found mesalazine to be effective in preventing acute diverticulitis in patients with symptomatic uncomplicated diverticular disease. The role of rifaximin or mesalazine in preventing diverticulitis recurrence, based on the results of 1 and 4 RCTs, respectively, remains unclear. RCTs found rifaximin and mesalazine to be effective in treating symptomatic uncomplicated diverticular disease. The use of probiotics in diverticular disease and in preventing acute diverticulitis occurrence/recurrence appears promising but unconclusive. Finally, the role of fibre in treating diverticulosis remains unclear. Conclusions Available evidence suggests that antibiotics have a role only in the treatment of complicated diverticulitis. It appears to be some evidence for a role for rifaximin and mesalazine in treating symptomatic uncomplicated diverticular disease. Finally, there is not currently adequate evidence to recommend any medical treatment for the prevention of diverticulitis recurrence.

show abstract

808 Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial of Mesalamine for the Prevention of Recurrence of Diverticulitis

Cited by 12 publications

References 0 publications

Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study

Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study

American Gastroenterological Association Institute Technical Review on the Management of Acute Diverticulitis

Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon

Contact Info

Product

Resources

About